NCT05530655View on ClinicalTrials.gov

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions
Prostate CancerRadiation ToxicityUrinary Complication
Interventions
DRUG

Lisinopril Tablets

This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.

Trial Locations (1)

14642

RECRUITING

Wilmot Cancer Institute, Rochester

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

University of Rochester

OTHER